Hostname: page-component-848d4c4894-nr4z6 Total loading time: 0 Render date: 2024-06-09T18:06:13.371Z Has data issue: false hasContentIssue false
  • English
  • Français

Prevalence of serotypes of Xanthomonas maltophilia from world-wide sources

Published online by Cambridge University Press:  15 May 2009

B. Schable ,
D. L. Rhoden ,
W. R. Jarvis  and
J. M. Miller
B. Schable*
Affiliation:
Hospital Infections Program, Centers for Disease Control, PHS, USDHHS, Atlanta, Georgia 30333
D. L. Rhoden
Affiliation:
Hospital Infections Program, Centers for Disease Control, PHS, USDHHS, Atlanta, Georgia 30333
W. R. Jarvis
Affiliation:
Hospital Infections Program, Centers for Disease Control, PHS, USDHHS, Atlanta, Georgia 30333
J. M. Miller
Affiliation:
Hospital Infections Program, Centers for Disease Control, PHS, USDHHS, Atlanta, Georgia 30333
*
*Nosocomial Pathogens Laboratory Branch. Centers for Disease Control. Mailstop GO7, Atlanta, Georgia 30333. Use of trade names is for identification only and does not imply endorsement by the Public Health Service or by the U.S. Department of Health and Human Services.
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Since its development in 1988, a serologic typing scheme for Xanthomonas maltophilia, based on 31 O antigens, has been successfully used to serotype isolates involved in nosocomial outbreaks in the United States. To determine if this serotyping scheme would be useful in typing X. maltophilia isolates from worldwide sources, we obtained additional isolates from 10 countries; of 900 isolates tested, 795 (88·3%) were typable. In order of predominance, the three most common serotypes were 10, 3 and 19. These three serotypes were most frequently associated with respiratory and blood isolates. This serotyping system is useful as an epidemiologic screening method for universal typing of outbreaks of X. maltophilia infections.

Type
Research Article
Information
Epidemiology & Infection , Volume 108 , Issue 2 , April 1992 , pp. 337 - 341
Copyright
Copyright © Cambridge University Press 1992

References

REFERENCES

1.Gilardi, GL. Pseudomonas maltophilia infections in man. Am J Clin Pathol 1969; 51: 58–61.CrossRefGoogle ScholarPubMed
2.Sutter, VL. Identification of Pseudomonas species isolated from hospital environment and human sources. Appl Environ Microbiol 1968; 16: 1532–8.CrossRefGoogle ScholarPubMed
3.Gardner, P, Griffin, WB, Swartz, MN, Kunz, LJ. Nonfermentative gram-negative bacilli of nosocomial interest. Am J Med 1970; 48: 735–49.CrossRefGoogle ScholarPubMed
4.Morrison, AJ, Hoffman, KK, Wenzel, RP. Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital. J Clin Microbiol 1986; 24: 52–5.CrossRefGoogle ScholarPubMed
5.Muder, RR, Yu, VL, Dummer, JS, Vinson, C, Lumish, RM. Infections caused by Pseudomonas maltophilia. Expanding clinical spectrum. Arch Intern Med 1987; 147: 1672–4.CrossRefGoogle ScholarPubMed
6.Khardori, N, Eltig, L, Wong, E, Schable, B, Bodey, G. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis 1990; 12: 997–1003.CrossRefGoogle ScholarPubMed
7.Felegie, TP, Yu, VLRumans, LW, Yee, RB. Susceptibility of Pseudomonas maltophilia to antimicrobial agents, singly and in combination. Antimicrob Agents Chemother 1979; 16: 833–7.CrossRefGoogle ScholarPubMed
8.Moody, MR, Young, VM, Kenton, DM. In vitro antibiotic susceptibility of pseudomonads other than Pseudomonas aeruginosa recovered from cancer patients. Antimicrob Agents Chemother 1972; 2: 344–9.CrossRefGoogle ScholarPubMed
9.Gilardi, GL. Infrequently encountered Pseudomonas species causing infections in humans. Ann Intern Med 1972; 77: 211–5.CrossRefGoogle Scholar
10.Nord, CE, Wadstrom, T, Wretlind, B. Synergistic effect of combinations of sulfamethoxazole, trimethoprim, and colistin against Pseudomonas maltophilia and Pseudomonas cepacia. Antimicrob Agents Chemother 1974; 6: 521–3.CrossRefGoogle ScholarPubMed
11.Yu, VL, Felegie, TP, Yee, RB, Pasculle, AW, Taylor, FH. Synergistic interaction in vitro with use of three antibiotics simultaneously against Pseudomonas maltophilia. J Infect Dis 1980; 142: 602–7.CrossRefGoogle ScholarPubMed
12.Zuravleff, JJ, Yu, VL. Infections caused by Pseudomonas maltophilia with emphasis on bacteremia: case reports and a review of the literature. Rev Infect Dis 1982; 4: 1236–46.CrossRefGoogle Scholar
13.Schable, B, Rhoden, DL, Hugh, R et al. , Serological classification of Xanthomonas maltophilia (Pseudomonas maltophilia) based on heat-stable O antigens. J Clin Microbiol 1989; 27: 1011–4.CrossRefGoogle ScholarPubMed
14.Dean, AG, Dean, JA, Burton, AH, Dicker, RC. Epi Info. Version 5: a word processing, database, and statistics program for epidemiology on microcomputers. Centers for Disease Control. Atlanta, Georgia, USA, 1990.Google Scholar
15.Pedersen, MM, Marso, E, Pickett, M. Nonfermentative bacilli associated with man: III. Pathogenicity and antibiotic susceptibility. Am J Clin Pathol 1970; 54: 178–92.CrossRefGoogle Scholar
16.Holmes, B, Lapage, SP, Easterling, BG. Distribution in clinical material and identification of Pseudomonas maltophilia. J Clin Pathol 1979; 32: 66–72.CrossRefGoogle ScholarPubMed
17.Schable, B, Villarino, ME, Favero, MS, Miller, JM. Application of multilocus enzyme electrophoresis to epidemiologic investigations of Xanthomonas maltophilia. Infect Control Hosp Epidemiol 1991; 12: 163–7.CrossRefGoogle ScholarPubMed